Mispro Biotech Services, North America's pioneering contract vivarium organization (CVO), is proud to announce its 20th anniversary and brand refresh to commemorate the occasion.
Since its founding in 2003, Mispro has established itself as a trusted partner for biotech and biopharma companies seeking high-quality laboratory animal research facilities and services. As the company marks its 20th year in business, the brand refresh aims to reflect the company's evolution while embodying its forward-thinking approach and dedication to growth.
With an established brand and reputation as a market leader, Mispro has opted for a distinct brand refresh rather than a drastic overhaul. The new branding features a clean, modern logo that retains the company's signature blue colors and streamlines the company's trade name to the concise, and familiar, "Mispro."
"We are thrilled to celebrate our 20th year and are committed to continuing our growth in existing and new markets," said Mispro CEO Philippe Lamarre. "Our brand refresh reflects our singular focus on providing the most effective, sensible, and ethical research environments for scalable preclinical drug development studies in the market. This is an exciting step for Mispro as we continue to look towards the future."
Mispro's new branding will be reflected in advertising, online, in its facilities, and at events celebrating the company's 20th anniversary.
To learn more about Mispro's brand refresh and logo, visit Mispro 2023 Rebrand or follow Mispro on Twitter and LinkedIn.
About Mispro
Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230321005085/en/
Contacts
For media inquiries:
jfogarty@mispro.com
